Brief: UK Drug Tariff rejects current Woulgan application
02/05/2017 21:50
May 2 (Reuters) - Biotec Pharmacon Asa BIOTEC.OL :
* UK Drug Tariff rejects current Woulgan application
* Subsidiary Biotec Betaglucan has received negative
feedback from uk drug tariff regarding application for
reimbursement
* management are considering if there are grounds for an
appeal in line with NHS' own guidelines
* UK Drug Tariff informed co that nhs has decided not to
list woulgan because they consider evidence provided to be
insufficient to document cost effectiveness
Source text for Eikon: urn:newsml:reuters.com:*:nWkr7Jj5k6
Further company coverage: BIOTEC.OL
((Bangalore.newsroom@thomsonreuters.com;))